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BACKGROUND: The United States Food and Drug Admin-
istration recently issued a warning about adverse events in
patients receiving inferior vena cava (IVC) filters.
OBJECTIVE: To assess relationships between IVC filter
insertion and complications while controlling for differences
in baseline patient characteristics and medical venous
thromboembolism prophylaxis.
DESIGN: Propensity-matched cohort study.
SETTING: The prospective, statewide, clinical registry of
the Michigan Bariatric Surgery Collaborative.
PATIENTS: Bariatric surgery patients (n535,477) from 32
hospitals during the years 2006 through 2012.
INTERVENTION: Prophylactic IVC filter insertion.
MEASUREMENTS: Outcomes included the occurrence of
complications (pulmonary embolism, deep vein thrombosis,
and overall combined rates of complications by severity)
within 30 days of bariatric surgery.
RESULTS: There were no significant differences in baseline
characteristics among the 1,077 patients with IVC filters and
in 1,077 matched control patients. Patients receiving IVC fil-
ters had higher rates of pulmonary embolism (0.84% vs
0.46%; odds ratio [OR], 2.0; 95% confidence interval [CI], 0.6-
6.5; P50.232), deep vein thrombosis (1.2% vs 0.37%; OR,
3.3; 95% CI, 1.1-10.1; P50.039), venous thromboembolism
(1.9% vs 0.74%; OR, 2.7; 95% CI, 1.1-6.3, P50.027), serious
complications (5.8% vs 3.8%; OR, 1.6; 95% CI, 1.0-2.4;
P50.031), permanently disabling complications (1.2% vs
0.37%; OR, 4.3; 95% CI, 1.2-15.6; P50.028), and death
(0.7% vs 0.09%; OR, 7.0; 95% CI, 0.9-57.3; P50.068). Of the
7 deaths among patients with IVC filters, 4 were attributable to
pulmonary embolism and 2 to IVC thrombosis/occlusion.
CONCLUSIONS: We have identified no benefits and signifi-
cant risks to the use of prophylactic IVC filters among bari-
atric surgery patients and believe that their use should be
discouraged. Journal of Hospital Medicine 2013;8:173–177.
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The use of inferior vena cava (IVC) filters has
increased substantially in recent years. These medical
devices, which are used to prevent pulmonary embo-
lism in patients considered to be at high risk of
venous thromboembolism, were placed in 167,000
patients in 2007.1 In 2012, it is estimated that
259,000 patients will undergo placement of an IVC
filter, an increase of 55%.1 Increasing use of IVC fil-
ters is attributable to the development of retrievable
versions of the devices, which have expanded indica-
tions for use such as in bariatric surgery.
Unfortunately, the increase in the use of IVC filters
has been accompanied by an increase in reports of
adverse events in patients receiving them. The United
States Food and Drug Administration (FDA) has
received more than 900 adverse event reports involv-
ing IVC filters, prompting the agency to issue a warn-
ing about their use.2 A prior study by our group
demonstrated a lack of benefit of IVC filter insertion
for the prevention of pulmonary embolism among
bariatric surgery patients but lacked statistical power
to prove harms associated with this practice.3
In the current study, we analyzed data from the pro-
spective, statewide, clinical registry of the Michigan
Bariatric Surgery Collaborative. Our study population
now includes 35,477 bariatric surgery patients from 32
hospitals whose procedures were performed between
2006 and 2012. Since the publication of our prior
study, the use of IVC filters in bariatric surgery has
decreased significantly in Michigan. For this reason,
our study population now includes many more high-
risk patients who did not undergo IVC filter placement,
allowing us to match IVC filter patients to similarly
high-risk patients who did not receive IVC filters. We
used these data to compare outcomes within 30 days of
surgery, including rates of venous thromboembolism,
overall serious complications, and death among
patients who did and not receive IVC filters.
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METHODS
Study Setting
The Michigan Bariatric Surgery Collaborative (MBSC)
is a regional voluntary consortium of hospitals and
surgeons that perform bariatric surgery in Michigan.
The goal of the project is to improve the quality of
care for patients undergoing bariatric surgery. To do
this, the participating hospitals submit data to the
MBSC clinical outcomes registry, patient survey, and
surgeon survey databases. Three times per year the
group meets to examine these data and to design and
implement changes in care to improve the outcomes
of care for bariatric patients. The project is funded by
Blue Cross and Blue Shield of Michigan/Blue Care
Network and coordinated by faculty and staff mem-
bers from the Center for Healthcare Outcomes and
Policy at the University of Michigan.
The MBSC held its first collaborative meeting in
June 2005 and enrolled its first patient in June 2006.
The MBSC now has the participation of all of the 32
bariatric programs in Michigan, enrolling approxi-
mately 6000 patients per year in its clinical registry.
Participating hospitals submit data from a review of
the medical records for all of their bariatric surgery
patients. This review is conducted for each patient at
30 days after surgery. The information collected
includes preoperative clinical characteristics and con-
ditions as well as perioperative clinical care and out-
comes. The medical record reviews are performed by
centrally trained, nurse data abstractors using a stand-
ardized and validated instrument. Each participating
hospital is site visited annually to verify the accuracy
and completeness of their MBSC clinical registry data.
Study Population
This study includes data for 35,477 patients under-
going bariatric surgery, including: 9829 laparoscopic
adjustable gastric band, 6068 sleeve gastrectomy,
19,141 gastric bypass, and 439 biliopancreatic diver-
sion with duodenal switch procedures between June
2006 and September 2012. Patients undergoing revi-
sional bariatric surgery were excluded from these
analyses. Prior to surgery, 1077 (3.0%) of these
patients had a prophylactic IVC filter placed for pre-
vention of pulmonary embolism. Of the IVC filters
placed, 39% were temporary IVC filters, 45% were
permanent IVC filters, and the type of IVC filter was
not known in 15%.
Baseline Clinical Characteristics
Data collected included patient demographic charac-
teristics (age, gender, race, type of insurance), clinical
characteristics (height, weight, history of cigarette
smoking, mobility limitations), and obesity-related
and other comorbid conditions (lung disease, cardio-
vascular disease, hyperlipidemia, gastroesophageal
reflux disease, peptic ulcer disease, cholelithiasis, uri-
nary incontinence, renal disease, diabetes, liver dis-
ease, prior history of venous thromboembolism, sleep
apnea, and psychological disorders).
Risk factors for VTE were empirically derived from
our data base using multivariate statistical models.
Risk factors for VTE included: age, body mass index,
male sex, current or past smoking, mobility limita-
tions, asthma, home oxygen use, peripheral vascular
disease, prior history of VTE, bariatric procedure
time, and procedure type. The baseline predicted risk
for VTE was calculated for each patient based on
these risk factors and was used to divide patients into
low- (predicted risk <1%), medium- (predicted risk
1%–2.5%), and high- (predicted risk 2.5%) risk
groups. Among the 35,477 patients in the registry
overall, 95% are in the low-risk group, 4% are in the
medium-risk group, and 1% are in the high-risk
group. In the matched study cohorts, 69%, 22%, and
9% were in the high-, medium-, and low-risk groups,
respectively.
Medical Venous Thromboembolism Prophylaxis
Data were also collected regarding the type of medical
venous thromboembolism prophylaxis (unfractionated
vs low molecular weight heparin) used preoperatively,
postoperatively, and whether the patient was dis-
charged to home on low molecular weight heparin.
Outcomes
Our primary outcome measures included postopera-
tive venous thromboembolism (deep vein thrombosis
or pulmonary embolism requiring treatment). We also
assessed overall rate of complications and complica-
tions according to severity as follows: non-life threat-
ening complications (surgical site infection including
wound and port site infections treated with antibiotics
and/or wound opening, anastomotic stricture requir-
ing dilatation, bleeding requiring blood transfusion of
<4 units, and pneumonia requiring treatment with
antibiotics only); potentially life-threatening complica-
tions (abdominal abscess requiring percutaneous
drainage or reoperation, bowel obstruction requiring
reoperation, leak requiring percutaneous drainage or
reoperation, bleeding requiring transfusion >4 units,
reoperation, or splenectomy, band-related problems
requiring reoperation, respiratory failure requiring 2
to 7 days intubation, renal failure requiring in-hospital
dialysis, wound infection/dehiscence requiring reoper-
ation, and venous thromboembolism); and life-threat-
ening complications associated with residual and
lasting disability or death (myocardial infarction or
cardiac arrest, renal failure requiring long-term dialy-
sis, respiratory failure requiring >7 days intubation or
tracheostomy, and death). Other complications that
are not included in these categories (eg, IVC filter
related) were assessed by an end points committee to
determine their severity (non-life threatening, poten-
tially life threatening, or life threatening associated
with residual and lasting disability or death).
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Statistical Analyses
We used propensity score matching to assemble
cohorts in which patients with and without IVC filters
were balanced on baseline characteristics. The proba-
bility of IVC filter placement was estimated for each
patient using a nonparsimonious multivariate logistic
regression model, in which IVC filter was the depend-
ent variable and all of the demographic, weight,
medical history, weight-related comorbidity, and pro-
cedure-related variables (type, length, and year of pro-
cedure; and medical venous thromboembolism
prophylaxis used) in our dataset were included as
covariates. IVC filter patients were matched to control
patients using a greedy, 1- to -1 matching without
replacement protocol resulting in cohorts that were
well balanced on all baseline characteristics.
Baseline characteristics and outcomes were then
compared among the cohorts using v2 and t tests as
appropriate. We used mixed effects logistic regression to
compare outcomes between the 2 treatment groups
while controlling for clustering at the hospital and sur-
geon level as random effects. Odds ratios (OR) and 95%
confidence intervals (CI) were calculated to compare
outcomes among patients with and without IVC filters.
RESULTS
Matching resulted in cohorts of IVC filter and control
patients who were well balanced on all baseline char-
acteristics (Table 1). In contrast, there were large and
significant differences between IVC filter patients and
unmatched control patients. For example, mean body
mass index was 58 and 57 in the matched cohorts
and 47 in the unmatched control patients. Prior his-
tory of venous thromboembolism was present in 39%,
39%, and 2% of the IVC filter, matched control, and
unmatched control patients, respectively. With regard
to procedure mix, unmatched control patients were
less likely to have open gastric bypass and more likely
to have adjustable gastric band procedures than IVC
filter or matched control patients.
With regard to outcomes (Table 2, Figures 1 and
2), IVC filter patients had significantly higher rates of
venous thromboembolism (1.9% vs 0.74%; OR, 2.7;
TABLE 1. Patient Characteristics in the








No. 1077 1077 33,323
Age (mean, y) 48 49 0.295 46 <0.0001
Body mass index (mean, kg/m2) 58 57 0.061 47 <0.0001
Male gender (%) 32 31 0.546 21 <0.0001
Black race (%) 27 25 0.667 15 <0.0001
Private Insurance (%) 62 64 0.305 74 <0.0001
Smoking in past year (%) 2 2 0.883 2 0.440
Mobility limitations (%) 18 18 0.780 5 <0.0001
Lung dsease (%) 43 43 1.000 25 <0.0001
Cardiovascular disease (%) 21 21 0.874 10 <0.0001
Hypertension (%) 72 72 0.737 53 <0.0001
Hyperlipidemia (%) 59 59 0.930 50 <0.0001
GERD (%) 50 52 0.490 49 0.417
Peptic ulcer disease (%) 5 4 0.228 3 <0.0001
Cholelithiasis (%) 30 30 0.963 27 0.018
Urinary incontinence (%) 25 25 0.960 22 0.029
Renal failure (%) 0.4 0.6 0.526 0.2 0.298
Diabetes (%) 46 48 0.546 33 <0.0001
Liver disorder (%) 4 4 0.584 5 0.184
Prior history of VTE (%) 39 39 0.965 2 <0.0001
Sleep apnea (%) 70 68 0.209 43 <0.0001
Musculoskeletal disorder (%) 78 80 0.221 77 0.189
History of hernia repair (%) 5 6 0.924 3 <0.0001
Psychological disorder (%) 49 49 0.796 47 0.267
Total comorbidities (mean, no.) 6 6 0.922 4 <0.0001
Procedure
Adjustable gastric banding (%) 15 17 0.099 29 <0.0001
Sleeve gastrectomy (%) 12 13 0.515 17 <0.0001
Gastric bypass (%) 73 69 0.058 53 <0.0001
Duodenal switch (%) 0.7 0.8 0.616 1.3 <0.0001
Procedure Length (mean, minutes) 114 116 0.427 95 <0.0001
Medical VTE prophylaxis
Preoperative heparin:
Unfractionated (%) 36 38 0.246 34 0.306
Low molecular weight (%) 60 54 0.017 53 <0.0001
Postoperative heparin:
Unfractionated (%) 7 10 0.023 19 <0.0001
Low molecular weight (%) 70 68 0.326 64 <0.0001
Postdischarge heparin:
Low molecular weight (%) 72 66 0.003 16 <0.0001
NOTE: Abbreviations: GERD, gastroesophageal reflux disease; IVC, inferior vena cava; VTE, venous
thromboembolism.
TABLE 2. Relationship Between Inferior Vena Cava




Venous thromboembolism 2.7 1.1–6.3 0.027
Deep vein thrombosis 3.3 1.1–10.1 0.039
Pulmonary embolism 2.0 0.6–6.5 0.232
Low-risk subgroup 1.0 0.1–7.7 0.965
Medium-risk subgroup 2.5 0.5–12.7 0.288
High-risk subgroup 2.2 0.2–24.3 0.530
Any complication 1.3 1.0–1.7 0.048
Serious complication 1.6 1.0–2.4 0.031
Permanently disabling complication 4.3 1.2–15.6 0.028
Death 7.0 0.9–57.3 0.068
FIG. 1. Rates of pulmonary embolism, deep vein thrombosis, and venous
thromboembolism in patients receiving prophylactic inferior vena cava (IVC)
filters and in matched controls.
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95% CI, 1.1-6.3; P50.027) and deep vein thrombosis
(1.2% vs 0.37%, OR, 3.3; 95% CI, 1.1-10.1;
P50.039) than matched control patients. Rates of
pulmonary embolism were higher among IVC filter
patients, but the difference was not statistically signifi-
cant (0.84% vs 0.46%; OR, 2.0; 95% CI, 0.6-6.5;
P50.232). Rates of pulmonary embolism were similar
for patients with a low baseline risk of venous throm-
boembolism (0.27% vs 0.27%; OR, 1.0; 95% CI,
0.1-7.7; P50.965) but were higher for medium-risk
patients (2.1% vs 0.87%; OR, 2.5; 95% CI, 0.5-12.7;
P50.288) and high-risk patients (2.1% vs 0.97%;
OR, 2.2; 95% CI, 0.2-24.3; P50.530).
Rates of other complications were also higher
among IVC filter than matched control patients (Table
2 and Figure 3). There were significantly higher rates
of complications (15.2% vs 11.6%; OR, 1.3; 95% CI,
1.0-1.7; P50.048), serious complications (5.8% vs
3.8%; OR, 1.6; 95% CI, 1.0-2.4; P50.031), and
permanently disabling complications (1.2% vs 0.4%;
OR, 4.3; 95% CI, 1.2-15.6; P50.028) among IVC fil-
ter patients. Rates of death (0.7% vs 0.1%; OR, 7.0;
95% CI, 0.9-57.3; P50.068) were also higher among
IVC filter patients than matched control patients, but
this difference was not statistically significant.
Among the 7 IVC filter patients who died, 4 had
fatal pulmonary embolism, and 2 had IVC filter
thrombosis/occlusion. Other IVC filter-specific compli-
cations included IVC filter migration requiring heart
valve replacement surgery in 1 patient, contrast-
induced nephropathy in 1 patient, IVC filter incision
site infection in 1 patient, and technical difficulties
removing a temporary IVC filter requiring that the
device stay in place in 1 patient.
DISCUSSION
In this propensity matched, observational cohort
study, we assessed the safety and effectiveness of
prophylactic IVC filters among bariatric surgery
patients. We found that patients with IVC filters had
significantly worse outcomes than comparably high-
risk patients without IVC filters. Rates of venous
thromboembolism were higher in the IVC filter
patients, and a large proportion of the other compli-
cations among IVC filter patients were device
related.
Our current study of IVC filters was prompted by
an FDA advisory report regarding complications in
patients receiving IVC filters.2 The FDA’s report was
in turn prompted by a study indicating a high preva-
lence of strut fracture and embolization among 80
patients who received a certain type of retrievable
IVC filter.4 The FDA conveyed receiving 921 adverse
events reports involving IVC filters between 2005 and
2009. Thirty-six percent of these reports involved
migration of the device, 16% were related to breakage
and embolization of parts of the device, and 8%
involved perforation of the IVC.
Research on the safety and efficacy of IVC filters in
bariatric surgery patients has largely been limited to
small, single-center, case series or cohort studies.5–15
A systematic review of this literature concluded that
the evidence was insufficient to recommend IVC filters
for patients undergoing bariatric surgery.16 A 2010
study by our group was the largest and only multi-
center study of IVC filters in the bariatric surgery
population. We found no benefit of IVC filters in a
comparison of 542 gastric bypass patients with pro-
phylactic IVC filters to 5,834 gastric bypass patients
without prophylactic IVC filters.3
When interpreting the results of this study, a num-
ber of limitations should be considered. Our study
was observational, so there is the potential for
unmeasured confounding variables to have influenced
our results. To minimize the risk of confounding, we
used propensity scores to match IVC filter patients to
comparably high-risk control patients, resulting in
study cohorts that were well balanced on all baseline
variables. Although this method accounts for con-
founding on the variables for which there are data,
there is still the possibility that an unknown con-
founder could affect our findings. For example, our
clinical registry lacks data on hypercoagulable states,
so it is possible that a higher proportion of IVC filter
patients could have had this risk factor and therefore
FIG. 2. Rates of pulmonary embolism in patients receiving prophylactic
inferior vena cava (IVC) filters and in matched control patients according to
baseline risk of venous thromboembolism.
FIG. 3. Rates of complications according to severity in patients receiving
prophylactic inferior vena cava (IVC) filters and in matched controls.
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a higher baseline risk of venous thromboembolism.
However, most patients with a hypercoagulable state
would have had a prior history of venous throm-
boembolism, which is a variable included in our data-
base that patients were matched on.
The effects of changes in clinical care occurring dur-
ing the time frame of this study should be considered in
interpreting our findings. For example, bariatric surgery
has been getting safer in general over time. Rates of
death have fallen both in Michigan and in the rest of
the country as bariatric surgeons have gained experi-
ence with this procedure. In Michigan during this time
period, our group has developed and implemented a
risk-stratified, standardized approach to venous throm-
boembolism prophylaxis for patients undergoing bari-
atric surgery. For these reasons, we included the year of
the procedure and the type of medical venous throm-
boembolism prophylaxis (unfractionated or low molec-
ular weight heparin) used perioperatively as a matching
variable in our analysis.
Another limitation that should be considered in inter-
preting our findings is statistical power. Although our
study is the largest in this study population to date,
many of the outcomes of interest are relatively rare.
Considering the entire bariatric surgery population,
rates of venous thromboembolism and death within 30
days are each less than 1%. Even in the high-risk
patients included in this analysis, there were a total of
just 28 (1.3%) venous thromboembolism events and 8
(0.37) deaths. Nonetheless, our study did find signifi-
cantly greater risks of multiple types of complications
among patients receiving IVC filters.
Finally, our study captures events occurring within 30
days of bariatric surgery. Complications, including ve-
nous thromboembolism and other complications directly
related to IVC filters, frequently occur after 30 days of
bariatric surgery. Therefore, our study may be a conserv-
ative estimate of the risks associated with the use of IVC
filters in bariatric surgery patients. Furthermore, certain
brands of filters have been shown to be associated with
higher risks of complications. Our study lacks data on
the brand of IVC filter used and so cannot assess the
extent to which this would affect our results.
CONCLUSIONS
In conclusion, our study indicates that IVC filters do
not reduce the risk of pulmonary embolism in high-
risk bariatric surgery patients. They are also associ-
ated with other complications attributable to malfunc-
tions of the device itself. We believe that the use of
IVC filters among bariatric surgery patients should be
discouraged.
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